A protein sits in the wrong part of the cell in some pituitary tumors
Original title: Nuclear exclusion of menin drives functional MEN1 deficiency in non-MEN1 prolactinomas: mouse models and human biopsies
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
Most of this was done in mice, with only a few human tissue samples.
The short version
In these tumors, a protein that helps hold back growth was pushed out of the cell's core.
What was studied. Scientists studied prolactinomas, a common pituitary tumor that makes too much of the hormone prolactin. They looked at two mouse models of these tumors and at human pituitary tissue samples.
What they found. The mice still made the menin protein, but in tumor cells it was not inside the cell nucleus. It stayed outside the nucleus instead, and growth signals in those cells went up. Drugs called dopamine agonists kept menin inside the nucleus, while blocking dopamine or giving estradiol pushed it out.
What this means, and what it doesn't
What it could mean: Prolactinomas are often treated with dopamine agonist pills. This work points to one possible reason those pills may help. Nothing about your care changes today.
What it doesn't mean: This does not mean there is a new treatment. Most of the work was done in mice, with a few human tissue samples. No new drug was tested in patients here. It is early lab science, far from everyday care, and it is not a cure.
Source: bioRxiv (preprint), August 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.